Literature DB >> 16170377

UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination.

Mitsuchika Hosoda1, Toshinori Ozaki, Kou Miyazaki, Syunji Hayashi, Kazushige Furuya, Ken-Ichi Watanabe, Takahito Nakagawa, Takayuki Hanamoto, Satoru Todo, Akira Nakagawara.   

Abstract

p73 protein level is kept extremely low in mammalian cultured cells and its stability may be regulated by not only the ubiquitin/proteasome-dependent proteolysis but also through other unidentified mechanisms. Here, we found for the first time that p73 is physically as well as functionally associated with the U-box-type E3/E4 ubiquitin ligase UFD2a. The immunoprecipitation experiments demonstrated that this interaction is mediated by the COOH-terminal region of p73alpha containing SAM domain. During the cisplatin-induced apoptosis in SH-SY5Y neuroblastoma cells, p73alpha accumulated at a protein level, whereas the endogenous UFD2a was significantly reduced in response to cisplatin. Ectopic expression of UFD2a decreased the half-life of p73alpha in association with a significant inhibition of the p73alpha-mediated transactivation as well as proapoptotic activity. Downregulation of endogenous UFD2a by antisense strategy resulted in a remarkable accumulation of p73alpha. Unexpectedly, UFD2a-mediated degradation of p73alpha was sensitive to the proteasomal inhibitor, however, UFD2a did not affect the ubiquitination levels of p73alpha. Taken together, our present findings imply that UFD2a might promote the proteasomal turnover of p73 in a ubiquitination-independent manner, and also suggest that UFD2a might play an important role in the regulation of cisplatin-induced apoptosis mediated by p73. Oncogene (2005) 24, 7156-7169. doi:10.1038/sj.onc.1208872; published online 19 September 2005.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16170377     DOI: 10.1038/sj.onc.1208872

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  28 in total

Review 1.  Ubiquitin and ubiquitin-like modifications of the p53 family.

Authors:  Ian R Watson; Meredith S Irwin
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

Review 2.  Therapeutic prospects for p73 and p63: rising from the shadow of p53.

Authors:  Anna Vilgelm; Wael El-Rifai; Alexander Zaika
Journal:  Drug Resist Updat       Date:  2008-09-17       Impact factor: 18.500

3.  U-box-type ubiquitin E4 ligase, UFD2a attenuates cisplatin mediated degradation of DeltaNp63alpha.

Authors:  Aditi Chatterjee; Sunil Upadhyay; Xiaofei Chang; Jatin K Nagpal; Barry Trink; David Sidransky
Journal:  Cell Cycle       Date:  2008-02-19       Impact factor: 4.534

4.  The antiapoptotic DeltaNp73 is degraded in a c-Jun-dependent manner upon genotoxic stress through the antizyme-mediated pathway.

Authors:  Iqbal Dulloo; Ganesan Gopalan; Gerry Melino; Kanaga Sabapathy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-25       Impact factor: 11.205

5.  Ubiquitin ligase Ufd2 is required for efficient degradation of Mps1 kinase.

Authors:  Chang Liu; Dewald van Dyk; Vitnary Choe; Jing Yan; Shubhra Majumder; Michael Costanzo; Xin Bao; Charles Boone; Keke Huo; Mark Winey; Harold Fisk; Brenda Andrews; Hai Rao
Journal:  J Biol Chem       Date:  2011-11-01       Impact factor: 5.157

6.  UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53.

Authors:  Hong Wu; Scott L Pomeroy; Manuel Ferreira; Natalia Teider; Juliana Mariani; Keiichi I Nakayama; Shigetsugu Hatakeyama; Victor A Tron; Linda F Saltibus; Leo Spyracopoulos; Roger P Leng
Journal:  Nat Med       Date:  2011-02-13       Impact factor: 53.440

Review 7.  A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression.

Authors:  D Engelmann; C Meier; V Alla; B M Pützer
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

8.  The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation.

Authors:  Yong-Sam Jung; Yingjuan Qian; Xinbin Chen
Journal:  J Biol Chem       Date:  2011-08-18       Impact factor: 5.157

9.  A gene signature-based approach identifies mTOR as a regulator of p73.

Authors:  Jennifer M Rosenbluth; Deborah J Mays; Maria F Pino; Luo Jia Tang; Jennifer A Pietenpol
Journal:  Mol Cell Biol       Date:  2008-08-04       Impact factor: 4.272

10.  1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model.

Authors:  Yingyu Ma; Wei-Dong Yu; Pamela A Hershberger; Geraldine Flynn; Rui-Xian Kong; Donald L Trump; Candace S Johnson
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.